Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2021005215
document
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma subtype. This retrospective study elucidates the currently unknown genetic background of a large clinically well-annotated cohort of DLBCLwith osseous localizations (O-DLBCL), including PB-DLBCL. A total of 103 patients with O-DLBCL were included and compared with 63 (extra)nodal non-osseous (NO)-DLBCLs with germinal center B-cell phenotype (NO-DLBCL-GCB). Cell-of-origin was determined by immunohistochemistry and gene-expression profiling (GEP) using (extended)-Nano-String/Lymph2Cx analysis. Mutational profileswere identifiedwith targeted next-generation deep sequencing, including 52 B-cell lymphoma-relevant genes. O-DLBCLs, including 34 PB-DLBCLs, were predominantly classified...
Ruben Al de Groen, Ronald van Eijk, Stefan Boehringer, Tom van Wezel, Richard Raghoo, Dina Ruano, Patty M Jansen, Inge Briaire-de Bruijn, Fleur A de Groot, Karin Kleiverda, Liane Te Boome, Valeska Terpstra, Henriette Levenga, Alina Nicolae-Cristea, Eduardus Franciscus Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C E den Hartog, Lara H Bohmer, Pancras C W HogendoornAnke van den Berg, Arjan Diepstra, Marcel Nijland, Pieternella J Lugtenburg, Marie José Kersten, Steven T Pals, Hendrik Veelken, Judith V M G Bovee, Arjen Cleven, Joost S P Vermaat
Clues for disease progression at time of diagnosis in patients with primary cutaneous follicle center lymphoma
Anne M. R. Schrader, Ruben A. L. de Groen, Rein Willemze, Patty M. Jansen, Koen D. Quint, Tom van Wezel, Ronald van Eijk, Dina Ruano, Arjan Diepstra, Anke van den Berg, Naomi Kakiailatu, Maarten H. Vermeer, Joost S. P. Vermaat
Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
Published in: British Journal of Haematology
Access to document
10.1111/bjh.17362
document
Individually, tissue and soluble markers involved in the programmed cell death protein 1/programmed death-ligand (PD-1/PD-L) axis have been described as biomarkers with clinical value in classical Hodgkin lymphoma (cHL). In the context of the success of immune checkpoint blockade therapy in cHL, it is interesting to discover whether plasma levels of proteins in the PD-1/PD-L axis are a reflection of expression by the corresponding tissue. Paired tissue and plasma samples of cHL patients were collected and analysed for PD-1, PD-L1 and PD-L2 levels. In addition, vascular endothelial growth...
Johanna Veldman, Zainab N D Alsada, Anke van den Berg, Wouter J Plattel, Arjan Diepstra, Lydia Visser
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
Published in: Targeted oncology
Access to document
10.1007/s11523-021-00798-2
document
Background The clinical relevance of epidermal growth factor receptor (EGFR) copy number gain in patients with EGFR mutated advanced non-small cell lung cancer on first-line tyrosine kinase inhibitor treatment has not been fully elucidated. Objective We aimed to estimate EGFR copy number gain using amplicon-based next generation sequencing data and explored its prognostic value. Patients and Methods Next generation sequencing data were obtained for 1566 patients with non-small cell lung cancer. EGFR copy number gain was defined based on an increase in EGFR read counts relative to internal...
Jiacong Wei, Pei Meng, Miente Martijn Terpstra, Anke van Rijk, Menno Tamminga, Frank Scherpen, Arja Ter Elst, Mohamed Z Alimohamed, Lennart F Johansson, Jos Stigt, Rolof P G Gijtenbeek, John van Putten, T Jeroen N Hiltermann, Harry J M Groen, Klaas Kok, Anthonie J van der Wekken, Anke van den Berg
Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development
Published in: Cancers
Access to document
10.3390/cancers13030414
document
Simple Summary Hodgkin lymphoma (HL) is a common lymphoma in young adults derived from B cells. Emerging evidence suggests that antigen presentation by the malignant B cells is critically involved in HL pathogenesis. In fact, genetic variants of the antigen presenting Human Leukocyte Antigens (HLA) are strongly associated with HL susceptibility. Interestingly, the endoplasmic reticulum aminopeptidase (ERAP)1 and ERAP2 genes, that code for enzymes that process antigens, also appear to be associated. In this study, we show that genetic variants of ERAP genes strongly affect expression levels of...
Peijia Jiang, Rianne N Veenstra, Annika Seitz, Ilja M Nolte, Bouke G Hepkema, Lydia Visser, Anke van den Berg, Arjan Diepstra